SCHEDULE: Millennium Management Discloses Stake in Perspective Therapeutics

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G, reporting beneficial ownership of 4,893,883 shares, or 4.3%, of Perspective Therapeutics, Inc. common stock.

Summary

• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have entered into a joint filing agreement to report their beneficial ownership of Perspective Therapeutics, Inc. common stock.
• The filing indicates that as of June 23, 2026, the reporting persons collectively held 4,893,883 shares of common stock, representing 4.3% of the class.
• The reporting persons state that they ceased to be beneficial owners of more than 5% of the outstanding common stock by the date of this filing (June 29, 2026).
• The securities are held by entities subject to the voting control and investment discretion of Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Mr. Englander.
• The filing explicitly states that this should not be construed as an admission of beneficial ownership by Millennium Management LLC, Millennium Group Management LLC, or Mr. Englander for the securities held by such entities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily serves as a disclosure of beneficial ownership and does not contain operational or financial performance information that would typically influence investment sentiment.

Positives

• Disclosure of a significant institutional investor's stake in Perspective Therapeutics, Inc., which can signal confidence and potential for future investment.
• The filing confirms that the reporting persons are not seeking to influence or change control of the issuer, which may be viewed positively by existing management and board.

Negatives

• The reporting persons have ceased to be beneficial owners of more than 5% of the outstanding common stock by the filing date, suggesting a potential reduction in their stake or a shift in reporting thresholds.
• The complex ownership structure and disclaimer regarding beneficial ownership may create ambiguity for investors seeking clarity on control and influence.

Risks

• The disclaimer regarding beneficial ownership could indicate a complex or indirect control structure, potentially leading to uncertainty about the true extent of influence over the company.
• A reduction in beneficial ownership below the 5% threshold by the filing date could signal a decrease in the reporting persons' conviction or a strategic divestment.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding future performance or strategy of Perspective Therapeutics, Inc. It solely pertains to the reporting of beneficial ownership by Millennium entities.

Management Comments

• "The foregoing should not be construed in and of itself as an admission by Millennium Management LLC, Millennium Group Management LLC or Mr. Englander as to beneficial ownership of the securities held by such entities."
• "After acquiring beneficial ownership of more than 5% of the outstanding Common Stock on June 23, 2026, the reporting persons ceased to be beneficial owners of more than 5% of the outstanding Common Stock by the date of this filing."

Industry Context

StockSavvy.ai notes that this filing represents a standard Schedule 13G disclosure, indicating a passive investment stake by a significant investment management firm in a publicly traded company. Such filings are common and provide transparency regarding institutional holdings.

Stakeholder Impact

• Shareholders: Increased transparency regarding institutional ownership, potentially signaling stability or interest from large investors.
• Management: Confirmation that the reporting persons are not seeking to influence control, which may reduce immediate governance concerns.
• Regulators: Compliance with SEC reporting requirements for significant beneficial ownership.

Next Steps

• The reporting persons will continue to file amendments to this Schedule 13G as required by SEC regulations if there are any changes in their beneficial ownership.
• Perspective Therapeutics, Inc. will continue its business operations as disclosed in its other SEC filings.

Key Dates

Keywords

Schedule 13G, Millennium Management, Perspective Therapeutics, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Securities Exchange Act